

PATENT  
Attorney Docket No. 03806.0493-00000

U.S. Patent Application

of

Marie-Christine Bissery

for

A Composition Comprising  
Camptothecin or a Camptothecin Derivative and a Topoisomerase II Inhibitor  
for the Treatment of Cancer


03806.0493-00000

PATENT  
Attorney Docket No. 03806.0493-00000

The present application claims the benefit of U.S. Provisional Application No. 60/190,061 filed March 17, 2000.

The present invention relates to therapeutic compositions comprising an effective amount of camptothecin, or a camptothecin derivative, in combination with an effective amount of a topoisomerase II inhibitor for the treatment of cancer.

European patent EP 137,145, specifically incorporated by reference herein, describes camptothecin derivatives of the formula:



in which, in particular, R<sub>1</sub> is hydrogen, halogen or alkyl; X is a chlorine atom, or NR<sub>2</sub>R<sub>3</sub>, in which R<sub>2</sub> and R<sub>3</sub>, which may be identical or different, may represent a hydrogen atom, an optionally substituted alkyl radical, a carbocycle or a heterocycle which are optionally substituted, or alkyl radicals (optionally substituted) forming, with the nitrogen atom to which they are attached, a heterocycle optionally containing another heteroatom chosen

PATENT  
Attorney Docket No. 03806.0493-00000

from O, S, and/or NR<sub>4</sub>, wherein R<sub>4</sub> is a hydrogen atom or an alkyl radical; and in which the group X-CO-O- is located on ring A in position 9, 10, or 11.

These camptothecin derivatives are anticancer agents which inhibit topoisomerase I, among which irinotecan, in which X-CO-O- is [4-(1-piperidino-1-piperidino]carbonyloxy, is an active principle which is particularly effective in treatment of solid tumors. Camptothecin and camptothecin derivatives such as irinotecan (CPT-11) are cytotoxic alkaloids which possesses strong anti-tumor activities. Irinotecan shows clinical activity against colon, gastric, ovarian, and small cell lung cancers, as well as non-Hodgkin's lymphoma (Bissery, M. et al., *Anti Cancer Drugs*, 7:166-174 (1996)).

The European patent application EP 74,256 also describes other camptothecin derivatives which are also mentioned as anticancer agents, in particular, derivatives of a structure analogous to the structure given above and in which X-CO-O- is replaced with a radical -X'R' for which X' is O or S, and R' is a hydrogen atom or an alkyl or acyl radical.

Other camptothecin derivatives have also been described, for example, in the following publications, patents, or patent applications: EP 56,692; EP 88,642; EP 296,612; EP 321,122; EP 325,247; EP 540,099; EP 737,686; WO 90/03169; WO 96/37496; WO 96/38146; WO 96/38449; WO 97/00876; U.S. Pat. No. 7,104,894; JP 57 116,015; JP 57 116,074; JP 59 005,188; JP 60 019,790; JP 01 249,777; JP 01 246,287; and JP 91 12070; *Canc. Res.*, 38 (1997) Abstr. 1526 or 95 (San Diego, April

12-16); *Canc. Res.*, **55**(3):603-609 (1995); or *AFMC Int. Med. Chem. Symp.* (1997) Abstr. PB-55 (Seoul, Korea; July 27-August 1).

Camptothecin derivatives are usually administered by injection, more particularly intravenously in the form of a sterile solution or an emulsion. Camptothecin derivatives, however, can also be administered orally, in the form of solid or liquid compositions.

However, while camptothecin derivatives are considered as some of the most powerful substances possessing anti-tumor activity for colorectal cancers, the use of these compounds can be improved in clinical treatments by association with other antitumor agents.

Among such antitumor agents are topoisomerase II inhibitors, many of which possess antineoplastic properties. Some of these agents belong to the class of anthracycline antibiotics, such as daunorubicin, doxorubicin, annamycin, epirubicin, mitomycin, bleomycin, idarubicin (idamycin), and cororubicin. Other agents belong to the class of epipodophyllotoxins, such as etoposide (VP-16), and teniposide (VM-26).

The combination of CPT-11 and the anthracycline antibiotic, doxorubicin, has been studied in Japan (Furuta, Tomio et al., *Cancer Chemotherapy*, **18**(3): 393-402 (1991)). In that study, however, the evaluation of the combination was only conducted on L1210 mouse leukemia, not solid tumors. The route of administration of irinotecan and doxorubicin was via the abdominal cavity, that is, the drugs were administered intraperitoneally and not orally or intravenously. Furthermore, that study did not evaluate

the effect of the highest non-toxic dose of either camptothecin or doxorubicin as single agents. Without such a determination, it is not possible to determine the synergistic effect of the CPT-11/doxorubicin combination.

It has now been found that the combination of CPT-11 with a topoisomerase II inhibitor such as doxorubicin or etoposide is more active at a lower dose than the highest non-toxic dose of each single agent for the treatment of cancer, for example, in the treatment of pancreatic ductal adenocarcinoma and mammary adenocarcinoma.

The efficacy of a combination may be demonstrated by determination of therapeutic synergy. A combination manifests therapeutic synergy if it is therapeutically superior to one or other of the constituents used at its optimum dose (T.H. Corbett et al., *Cancer Treatment Reports*, **66**: 1187 (1982)).

The efficacy of a combination may also be demonstrated by comparison of the maximum tolerated dose of the combination with the maximum tolerated dose of each of the separate constituents in the study in question. This efficacy may be quantified, for example by the  $\log_{10}$  cell kill, which is determined by the following formula:

$$\log_{10} \text{cell kill} = T - C(\text{days}) / 3.32 \times T_d$$

in which T-C represents the time taken for the cells to grow, which is the mean time in days for the tumors of the treated group (T) to reach a predetermined value (1 g for example) and the tumors of the control group (C) to reach the same value, and  $T_d$  represents the time in days needed for the volume of the tumors in the control group to double. (T.H. Corbett et al., *Cancer*, **40**: 2660-2680 (1977); F.M. Schabel et al., *Cancer*

*Drug Development, Part B, Methods in Cancer Research, 17: 3-51, New York, Academic Press Inc. (1979)).* A product is considered to be active if the  $\log_{10}$  cell kill is greater than or equal to 0.7. A product is considered to be very active if the  $\log_{10}$  cell kill is greater than 2.8.

It has now been found that administration of CPT-11 in combination with doxorubicin in the following manner with the following schedules results in a combination that is synergistically active against pancreatic ductal adenocarcinoma, that is, the maximum tolerated dose of the CPT-11/doxorubicin combination is therapeutically superior to the maximum tolerated dose of either CPT-11 or doxorubicin alone.

The products may be administered simultaneously, semi-simultaneously, separately, or spaced out over a period of time so as to obtain the maximum efficacy of the combination. As a result, the invention is not limited to the compositions obtained by the physical association of the drugs, but also include those which permit separate administration, either simultaneously, semi-simultaneously, or spaced out over a period of time.

#### **Brief Description of the Drawing**

Figure 1 presents a table evaluating irinotecan (CPT-11), doxorubicin, and the combination thereof as therapeutics against pancreatic ductal adenocarcinoma in a murine model system.

**Example 1**

Irinotecan alone was tested in various murine models is indicated in Table I. The efficacy was measured by the  $\log_{10}$  cell kill (LCK). The optimal total dose for oral and intravenous administration routes was also determined.

**Table I:** Comparison of Oral and I.V. Irinotecan Administration

Tumor (mice)	Route	Schedule days	Optimal Total Dose mg/kg	LCK
C51 (BALB/c)	oral	5,7,9,13,15, twice daily*	845	2.5
	i.v.	5,7,9,13,15, twice daily*	615	3.0
C26 (BALB/c)	oral	3-7 twice daily*	558	0.9
	i.v.	twice daily*	228	0.7
P03 (B6D2F1)	oral	twice daily*	900	3.4 †
	i.v.	twice daily*	346.2	3.2 †
MA16/C (C3H/HeN)	oral	5-9	230.5	2.7
	i.v.	5-9	130.5	2.6
GOS (B6D2F1)	oral	3-7, twice daily*	900	2.1
	i.v.	3, 5, 7 twice daily*	346.2	2.2

\* The two administrations were 4 hours apart. † 1/5 tumor free survivor on day 120.

Both methods of administration, oral and intravenous, resulted in similar tolerance, as measured by body weight loss (8.5%), nadir (7 days post last administration), and recovery (5 days post nadir, i.e., 12 days post first administration). This study showed that the efficacy in tumor bearing mice was similar for oral and i.v.

irinotecan administration across all five tumor models tested in three different mice strains. The maximum tolerated oral dose for irinotecan was shown to be about 1.4 to 2.6 times the maximum tolerated i.v. dose.

**Example 2**

Cross-resistance between various agents was measured in murine leukemia cell lines. P388/CPT is a camptothecin-resistant leukemia that was established *in vitro* (*Biochem. Pharmacol.*, **45**: 339 (1993)) and maintained *in vivo* by i.p. passages in DBA2 female mice. The chemosensitivity of i.p. P388/CPT was evaluated with i.v. P388 sensitive reference drugs with different mechanisms of action. Antitumor efficacy was determined at the highest non-toxic dose as percent increase in life span (ILS), where:

$$\text{ILS} = 100 \times [(\text{median day of death (MDD) of treated mice}) - (\text{MDD control mice})] \div (\text{MDD control mice})$$

A minimal level of activity equals an ILS of greater than 26%. P388/CPT was found resistant to camptothecin s.c. and CPT-11, but sensitive to both doxorubicin and etoposide. These results show that this cell line was still sensitive to topoisomerase II inhibitors even when camptothecin resistance was present (Vrignaud, P. et al., *Proc. Amer. Assoc. Cancer Res.*, **35**: 363, Abstract No. 2163 (1994)). Table II tabulates the results from this study.

**Table II:**

Agents/ %ILS	P388	P388/CPT (TFS)	Comment
CPT (sc)	82	0	resistant
CPT-11 (i.v.)	91	0	resistant
doxorubicin (i.v.)	122	180	sensitive
etoposide (i.v.)	127	121	sensitive

**Example 3**

Simultaneous intravenous administration of irinotecan (CPT-11) and representative topoisomerase II inhibitors was evaluated and the results are shown in Table III.

**Table III:**

CPT-11 plus:	Tumor site	Schedule	% HNTD of single agents	Host recovery (days)	Therapeutic response
doxorubicin	PO3 sc	simult.	65	13	≥
etoposide	MA16/C sc	simult.	60	6	=

HNTD represents the highest nontoxic dose. ≥: Better dose response for the combination. =: Dose response for combination about equal to each agent alone.

Simultaneous administration of CPT-11 and a topoisomerase II inhibitor resulted in a therapeutic response that for the etoposide combination was about equal to the agents alone. For the doxorubicin combination, the therapeutic response was better than for the agents alone.

**Example 4**

The effect of the combination of CPT-11 and doxorubicin was evaluated a three-arm study in mice bearing pancreatic ductal adenocarcinoma PO3. In the first arm, three doses of CPT were given orally on days six through nine, twice a day. In the second arm, three doses of doxorubicin were given intravenously on days six and nine. In the combination third arm, five dosage levels of CPT-11 were administered orally on days six through nine, twice a day, with administration of five dosage levels of doxorubicin intravenously on days six and nine. This third arm illustrated an example of semi-simultaneous administration. In all three arms, the two daily administrations of CPT-11 were given four hours apart.

The results obtained in the study of single agents CPT-11 and doxorubicin and the combination CPT-11/doxorubicin are given in Table IV.

**Table IV:**  
**Evaluation of CPT-11 in Combination with Doxorubicin Against Pancreatic Ductal Adenocarcinoma PO3 on B6D2F<sub>1</sub> Female Mice CM-887**

Agent	Route	Dosage (mg/kg/adm)	Schedule (days)	Log <sub>10</sub> cell kill	T-C (days)	Time for median tumor to reach 1000 mg in days	Comments
CPT-11	p.o.; 0.2 ml	100.8	6-9 (twice/day)	1.3	9.8	26.2	HDT active
CPT-11	p.o.; 0.2 ml	62.5	6-9 (twice/day)	1.2	9.3	25.7	Active
CPT-11	p.o.; 0.2 ml	38.8	6-9 (twice/day)	0.5	4.0	20.4	Inactive
Doxorubicin	i.v.; 0.2 ml	10.0	6, 9	-*	-*	-*	HDT highly active
Doxorubicin	i.v.; 0.2 ml	6.2	6, 9	1.2	9.5	25.9	Active
Doxorubicin	i.v.; 0.2 ml	3.8	6, 9	1.0	7.5	23.9	Active
Doxorubicin + CPT-11	i.v., 0.2 ml p.o., 0.2 ml	5.0 80.6	6, 9 6-9 (twice/day)	-*	-*	-*	HDT highly active
Doxorubicin + CPT-11	i.v., 0.2 ml p.o., 0.2 ml	4.1 65.5	6, 9 6-9 (twice/day)	4.7	35.6	52.0	Highly active
Doxorubicin + CPT-11	i.v., 0.2 ml p.o., 0.2 ml	3.1 50.4	6, 9 6-9 (twice/day)	3.1	23.5	39.9	Highly active

Agent	Route	Dosage (mg/kg/adm)	Schedule (days)	Log <sub>10</sub> cell kill	T-C (days)	Time for median tumor to reach 1000 mg in days	Comments
Doxorubicin + CPT-11	i.v., 0.2 ml p.o., 0.2 ml	2.2 35.3	6, 9 6-9 (twice/day)	1.6	12.3	28.7	Active
Doxorubicin + CPT-11	i.v., 0.2 ml p.o., 0.2 ml	1.2 20.1	6, 9 6-9 (twice/day)	0.5	4.1	20.5	Inactive

HDT: highest dose tested; T-C: Tumor growth delay; p.o.: per os; i.v.: intravenous

\* There are no values presented because 4 out of 5 animals tested were tumor free survivors.  
The data comprising this table were compiled from Figure 1.

While irinotecan as a single agent was active at two dosages, it was not highly active. Doxorubicin alone and the doxorubicin/CPT-11 combination were both highly active. However, the combination was highly active at a much lower dosage than the single agents. For example, in the highly active combination dosage doxorubicin was present at 50% of the highly active single agent dose, and CPT-11 was present at 80% of the merely active dose. Further, the combination was highly active over a larger dosage range than either of the single agents, i.e., four of the five combination dosages tested were at least active, and three were even highly active. The combination allowed for much lower dosages, while maintaining activity. Therefore, the combination of CPT-11 and doxorubicin was synergistically active for the treatment of cancer.

**Example 5**

The effectiveness of irinotecan combination chemotherapy methods was tested in a dose response study in a murine tumor model. Three arms were evaluated for tolerance and efficacy. Tolerance was measured by mortality, body weight loss at nadir, host recovery time, and combination toxicity index. Efficacy end points for solid tumor models were tumor growth delay (T/C),  $\log_{10}$  cell kill (LCK, defined above), tumor regressions (i.e., complete remission (CR), or partial remission (PR)).

Combination toxicity index (CTI) was calculated as the sum of the fraction of  $LD_{10}$ 's for each agent used in each combination (*Cancer Treatment Reports*, **66**(5): 1187-1200 (1982)). The  $LD_{10}$  for the single agent was obtained by plotting the toxicity of that

agent and the dosage in mg/kg as a log probit graph. Subsequently, the CTI LD<sub>10</sub> was obtained by plotting as a log probit graph the observed lethality and the corresponding CTI calculated as the sum of the fraction of the LD<sub>10</sub> of each single agent. When the CTI equals one, only 50% of the LD<sub>10</sub>'s of each agent can be used in combination without additional toxicity, and when the CTI equals two, 100% of the LD<sub>10</sub>'s of each agent can be used in combination without additional toxicity.

Table V compares different application methods for representative topoisomerase II inhibitors alone and in combination, i.e., i.v. or per os (p.o.), as indicated.

**Table V:**

Agents	Tumor site	Schedule days	HNTD Dose mg/kg		LCK	CTI
CPT-11, p.o.	PO3, sc	6-9, twice daily	806	-	1.3	
doxorubicin, i.v.		6, 9	-	20.0	-*	
combination			644.8	10.0	-*	≈ 1.3
CPT-11, p.o.	MA16/C, sc	3-7	198.5	-	2.0	
etoposide, i.v.		3, 5, 7	-	90.0	2.2	
combination			144.0	40.5	2.1	≈ 1.2

HNTD represents the highest nontoxic dose. \* 4/5 tumor free survivors; the combination gave a superior dose response (efficacy at 4 dose levels)

This study confirmed the positive results obtained in Example 1. Irinotecan combined with doxorubicin at its highest non toxic dose resulted in 4/5 tumor free survivors. Irinotecan combined with etoposide gave no antagonist activity, and was more

PATENT  
Attorney Docket No. 03806.0493-00000

effective than CPT-11 alone. The CPT-11/etoposide combination at its highest non-toxic dose produced a  $\log_{10}$  cell kill of 2.1, which was superior to the  $\log_{10}$  cell kill of the highest non-toxic dose of CPT-11 as a single agent. The combination was therefore therapeutically superior to both of the single agents used at its optimum dose.

In conclusion, a combination of a topoisomerase II inhibitor, such as an anthracycline antibiotic, i.e., doxorubicin, daunorubicin, annamycin, or cororubicin, or an epipodophyllotoxin, i.e., etoposide (VP-16), or teniposide (VM-26), with irinotecan or other camptothecin derivative, is a highly active pharmaceutical composition and represents a new method for treating cancer.